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1. Introduction 
Hashimoto’s thyroiditis is a common autoimmune disorder, which causes significant 
morbidity. Its pathophysiological hallmark is lymphocytic infiltration of thyroid follicles 
resulting in autoimmune glandular destruction. Various studies have successfully outlined 
the genetic and environmental factors responsible for the causation of the disease. In this 
chapter we will discuss our current understanding of these factors and delineate how 
Hashimoto’s thyroiditis serves as a paradigm not just for disease of the thyroid gland, but 
also for autoimmune disease in the human body. Our focus is on the varying presentations 
of the disease and the relationship between Hashimoto’s thyroiditis and other autoimmune 
diseases frequently associated with it. The etiological factors and the pathophysiological 
changes which lead to the development of disease are discussed. Common diagnostic 
modalities are described, and the need for correlation between the various available 
diagnostic tests is explained. Various treatment strategies and the appropriate choice for 
different forms of presentation are discussed. Hashimoto’s encephalopathy, a rare 
complication, will be addressed separately as its unusual presentation often results in 
misdiagnosis of the underlying pathology. 
2. Background 
Hashimoto’s thyroiditis was first described in 1912 by Dr. Hakuru Hashimoto. Based on the 
histological findings, Hashimoto originally used the term “Struma Lymphomatosa.”  Over 
the years, this disease has been called by several names including lymphocytic thyroiditis, 
autoimmune thyroiditis, chronic thyroiditis, and lymph adenoid goiter. The debate about 
the relationship between Hashimoto’s thyroiditis and Graves’ disease has been ongoing for 
many decades as they  differ in clinical and immunological presentation. However, 
Hashimoto’s thyroiditis and Graves’ disease, which depict the two extremes of the clinical 
spectrum, are now included in a common entity called autoimmune thyroid disease. It is 
now believed that they share a common autoimmune pathology and are believed to be 
triggered by multiple genetic and environmental factors. Hashimoto’s thyroiditis was 
initially perceived as an uncommon disease and most cases were incidentally diagnosed 
through histopathological examination of the thyroid gland after thyroidectomy. The advent 
of newer diagnostic modalities with increased diagnostic sensitivity made it possible to 
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unveil more cases of Hashimoto’s thyroiditis. With the increasing number of cases, the 
association of Hashimoto’s thyroiditis with other autoimmune diseases is being studied 
extensively. Type 1 diabetes, multiple sclerosis, rheumatoid arthritis, celiac disease, vitiligo, 
and chronic urticaria have all been reported to be frequently associated with Hashimoto’s 
thyroiditis. 
3. Incidence and distribution of the disease 
Hashimoto’s thyroiditis is about 15-20 times more common in women than in men and 
frequently involves people between the ages of 30 and 50 years of age. Determining the exact 
incidence and prevalence rates for Hashimoto’s thyroiditis has been difficult due to variable 
expression of this disease. Some studies estimate that the current prevalence rate in the United 
States ranges between 0.3%-1.2% (Staii et al., 2010). Other studies estimate the prevalence 
among the general population to be approximately 2% (Wang et al., 1997). When attempts 
have been made to characterize the prevalence prospectively, with the aid of organized 
programs of ultrasound guided biopsy, the prevalence described has been at least 5%. It 
should be noted that studies employing the diagnostic modality of ultrasound guided biopsy 
have recorded prevalence rates higher than studies using other investigative modalities (Staii 
et al., 2010). The National Health and Nutrition Evaluation Study-3 (NHANES-3) study has 
shown the prevalence of subclinical and clinical hypothyroidism to be 4.6% and 0.3%, 
respectively, in the United States (Hollowell et al., 2002). The Whickham survey, an 
epidemiological study conducted in the United States, has revealed the prevalence of 
hypothyroidism to be 1.5% in females and less than 0.1% in males (Tunbridge et al., 1997).  
During the past few decades there has been a reported increase in the incidence of 
Hashimoto’s thyroiditis, which could be attributed to newer diagnostic modalities such as 
needle biopsies and serological tests, and their increased sensitivity when compared to the 
older methods. (McConahey et al., 1962). Studies about age-specific incidence rates of 
Hashimoto’s thyroiditis indicate the existence of a random distribution in both men and 
women and have shown an initial lag in the first few years of their life followed by a constant 
rate after this (Volpe et al., 1973). A few studies have suggested a slight increase in the 
prevalence of autoimmune thyroiditis in adolescent girls following use of iodized food 
products ingested to prevent iodine deficiency (Zois et al., 2003).  
4. Etiology 
The etiology of Hashimoto’s thyroiditis is considered to be multifactorial, involving the 
interplay of various environmental and genetic factors. Studies conducted on the genetic 
associations of Hashimoto’s thyroiditis have shown that the human leukocyte antigen 
(HLA) region, which plays a major role in other autoimmune disorders, is associated with 
development of Hashimoto’s thyroiditis (Fisher, G.F., 2000). The association of Hashimoto’s 
thyroiditis with various other autoimmune diseases has further reinforced the probable 
involvement of genetic factors in the etiology. The major histocompatability complex 
(MHC), cytotoxic T-lymphocyte association (CTLA-4) and the human leukocyte antigen 
(HLA) are the genetic factors which are purported to play a major role in the pathogenesis. 
The selection of thyroid cells in the thymus and presentation of antigens in the periphery are 
modulated by, the human MHC analog, HLA. The sensitivity and specificity of the affinity 
to bind the peptides and recognize T-cells is determined largely by the genetic 
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polymorphisms exhibited by the MHC molecule. The possible polymorphisms within the 
MHC molecules play a pivotal role in the predisposition to autoimmune disease (Gebe et al., 
2002). The association between the genetics of Hashimoto’s thyroiditis and HLA gene loci 
has been investigated by serotyping the HLA, and deoxyribonucleic acid (DNA) typing the 
sequence- specific oligonucleotides. Different subsets of HLA genes have been found to 
show varying degree of associations with Hashimoto’s thyroiditis in different races. The 
HLA class 1 and class 2 genes both showed association with Hashimoto’s thyroiditis in 
Asian populations, while only HLA class 1 demonstrated the association in Caucasians. (Wu 
et al., 1994). No significant associations have been found between Hashimoto’s thyroiditis 
and HLA class 3 or non-HLA genes of the HLA region (Hunt et al., 2001). An association 
between CTLA-4 and Hashimoto’s thyroiditis has been noted in significant number of cases 
(Einarsdottir et al., 2003). CTLA-4 plays a vital role in upholding immunological self 
tolerance in the body and its down regulation is believed to be the initiating step for the 
pathogenesis of Hashimoto’s thyroiditis as well as other autoimmune disorders such as 
Graves’ disease (Chistiakov & Turakulov, 2003).  
In addition to the genetic factors numerous external factors also play a vital role in the 
etiology of the disease, preferentially affecting genetically predisposed individuals. The 
common environmental factors which act as triggers to initiate the insult on thyroid tissue 
include infections, cytokine therapy, selenium and iodine intake. Epidemiological studies 
and animal models have shown that among the factors that initiate the process, iodine 
appears to be the most significant (Boukis et al., 1983). Some studies have established 
smoking as an important risk factor for the causation of hypothyroidism in patients with 
Hashimoto’s thyroiditis (Fukata et al., 1996).  
5. Pathogenesis  
The pathogenesis of Hashimoto’s thyroiditis is a complex multistep process which involves 
various genetic, environmental and immunological factors ( Figure 1). In a nut shell, loss of 
immune tolerance to normal thyroid cells leads to production of antibodies directed against 
thyroid tissue, which causes the destruction of the thyroid gland. The initial inflammatory 
changes in the disease process are triggered when genetically predisposed individuals are 
exposed to the above mentioned environmental factors. The major histocompatability 
complex (MHC) class 2 antigen presenting cells, which include dendritic cells and 
macrophages, invade the thyroid gland after the initial inflammatory process. These cells 
present the autoantigen components of the thyroid gland to the immune system for 
processing. Among the myriad of potential auto-antigens, thyroglobulin, the main protein 
produced in thyroid tissue, is believed to play a central role in the pathogenesis of this 
disease (Champion et al., 1991). The thyroglobulin protein has been reported to have 
approximately 40 different types of epitopes, which play a vital role in the pathogenesis of 
the disease (Male et al., 1985). In contrast to the epitope recognition pattern of normal 
individuals, the epitope recognition pattern of the antibodies in autoimmune thyroid 
disease is altered triggering immune and inflammatory processes (Dietrich et al., 1991). 
Thyroid peroxidase, an enzyme that catalyzes the oxidation of iodine, also plays a 
significant role as an autoantigen in the disease pathogenesis. Moreover, 180 different types 
of thyroid peroxidase antibodies have been identified, thus far. Studies have confirmed that 
even though antibodies against thyrotropin receptor and sodium iodide symporter have 
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been detected in patients with autoimmune thyroid disease, they do not play a significant 
role in the pathogenesis of this condition.  
 
Legend: APC = Antigen Presenting Cell 
Fig. 1. A schematic presentation of etiopathogenesis of Hashimoto’s thyroiditis. (Casselman, 
W, G., 1996). 
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The major step in the pathogenesis is the formation of autoreactive cells directed against the 
thyroid gland, which could result from defects in central tolerance or defects in the 
peripheral tolerance. Loss of immune tolerance has been associated with genetically 
determined immune defects or with the lack of regulatory T-cells which impose the 
suppressive function (Martin, 1992). This is followed by formation, clonal expansion, and 
maturation of self-reactive T-lymphocytes and B-lymphocytes in the draining lymph nodes. 
This step is then followed by a central phase of autoimmunity, characterized by 
uncontrolled production of self-reactive cells and autoantibodies in response to the 
presented antigens. This process initially occurs in the lymph nodes but as the disease 
progresses the production process shifts to the thyroid gland where the development of 
lymphoid tissue follows. The stimulated B-lymphocytes produce antithyroglobulin (TGAB) 
and antithyroid peroxidase (ATPO) antibodies which are directed against thyroid cells. The 
autoreactive T-cells, which are produced in the disease process, infiltrate the thyroid gland 
and mediate destruction through cytotoxicity with the aid of CD+8 cells. The macrophages 
which are stimulated in this process produce numerous cytokines which, along with 
antibodies, initiate the process of tissue destruction via apoptosis.  
As a final step in the process, caspases, which are self-activated through proteolytic 
cleavage, induce enzymes which are directly involved in the destruction of thyroid gland. In 
a normal thyroid gland, the production of new cells and the destruction of old cells are 
tightly regulated so that a constant proportion of functioning cells is always present. During 
the course of the disease, the control over destruction of cells in the thyroid gland is lost. 
Genetic susceptibility is one of the factors that plays a vital role in deregulation of the 
regular destructive mechanisms in the thyroid gland. Several other triggers which have an 
influence on the expression of Bcl-2, the apoptosis inhibitor, or Fasl membrane ligand also 
are crucial in the initiation of the apoptosis process (Giordano et al., 2001). Thyroid cells in 
tissue affected with Hashimoto’s thyroiditis, when compared to normal thyroid cells, are 
capable of producing more Fasl proteins leading to an increased tempo of apoptosis 
(Limachi & Basso, 2002). The severity of the disease and the clinical outcome are determined 
by the rate at which apoptosis occurs in the thyroid gland. Expression of these proteins has 
direct correlation to the severity of the disease and as the rate of apoptosis increases, the 
mass of hormonally-active thyroid tissue decreases resulting in diminished production of 
thyroid hormones and more significant disease manifestations. 
6. Signs and symptoms 
Thyroid hormone is capable of influencing the function of every cell in the body. The basic 
function of thyroid hormone is to increase the basal metabolic rate of the body. The 
symptoms of Hashimoto’s thyroiditis are predominantly due to decreased production of 
thyroid hormone, which occurs as a result of destruction of thyroid tissue, ultimately 
leading to decreased metabolism. Indeed, most symptoms are not manifested in the early 
stages of the disease; as the disease advances and the degree of hypothyroidism increases, 
the symptoms become more evident. The decreased production of thyroid hormone 
adversely affects various major organ systems. Dysfunction of the cardiovascular system is 
manifested as bradycardia, while nervous system dysfunction manifests as slowed speech 
and delayed reflexes. Gastrointestinal symptoms include constipation, increased bile reflux 
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and ascites. When the metabolic rate drops to a critical level, a life threatening emergency 
called myxedema coma occurs. Myxedema is usually characterized by hypothermia, 
hypoglycemia, altered sensorium and severe bradycardia. In severely hypothyroid 
Individuals, triggers such as stress, infection, surgery and traumatic injuries may also 
predispose to the development of myxedema.  
In contrast to hypothyroid patients, patients in a euthyroid state do not experience any 
symptoms or exhibit any signs of the disease, and in most cases the diagnosis is 
incidental. Moreover, some individuals may not present with any clinical features except 
an enlarged thyroid gland and the diagnosis is made by investigating the goiter. The 
goiter, by itself, can cause cosmetic disfigurement in its initial stages and as its size 
increases, it can lead to pressure symptoms including pain in the neck, dysphagia, and 
dyspnea in some cases. Furthermore, a rapid growth in the goiter is sometimes noted, 
which should arouse suspicion for a tumor. Tumors of the thyroid gland, which 
sometimes arise in the background of Hashimoto’s thyroiditis, usually manifest as solitary 
or multiple nodules typically discovered incidentally during a regular physical 
examination. In addition to the previously noted symptoms, accumulation of  the matrix 
proteins, such as metalloproteases, might lead to swelling of the extremities and face. 
Though extremely rare in children, Hashimoto’s thyroiditis can lead to detrimental effects 
on growth and physical maturation. Moreover, short stature and mental retardation are 
the features which are most commonly observed in children suffering from Hashimoto’s 
thyroiditis.  
In addition to the symptoms of hypothyroidism, people suffering from Hashimoto’s 
thyroiditis sometimes experience symptoms due to other autoimmune diseases. Muscle pain 
is present in 25.5% of patients with Hashimoto’s thyroiditis. Rheumatic manifestations in 
autoiummune thyroiditis are reported to be ten times more frequent when compared to 
nonautoimmune thyroiditis. (Becker et al., 1963). Furthermore, the initial presentation 
sometimes can be very subtle. For instance, occasionally, irritatability, depression, 
confusion, and fatigue have been reported as initial complaints in patients later diagnosed 
with Hashimoto’s thyroiditis (Hall et al., 1982). Unfortunately, in many instances these cases 
were misdiagnosed as psychiatric disorders before being correctly diagnosed as due to 
thyroid hormone deficiency.  
7. Clinical course of the disease 
Hashimoto’s thyroiditis has a highly variable clinical presentation; patients may either be 
hypothyroid, euthyroid or hyperthyroid. About 20% of the patients exhibit signs and 
symptoms of mild hypothyroidism at the initial presentation. However, the severity of the 
symptoms increases with the progression of the disease (Gordin et al., 1974). This increase in 
the severity of symptoms is attributed to gradual destruction of the thyroid gland. 
Furthermore, as the hypothyroidism worsens, the patient is at increased risk of developing 
myxedema coma as a result of complete thyroid atrophy (Buchanan & Harden, 1965). A 
goiter, usually with gradual enlargement of the gland, may be the sole presentation in some 
instances. (Tunbridge et al., 1977). The other features which are usually associated with 
Hashimoto’s thyroiditis are not exhibited along with the goiter. 
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Fig. 2. Symptoms and signs of hypothyroidism based on specific pathophysiology  
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Some patients are initially euthyroid and are at risk of developing hypothyroidism as the 
disease progresses. The concomitant presence of a goiter along with elevated thyroid 
antibody levels, at presentation, has been found to increase the risk of hypothyroidism 
(Radetti et al., 2006). Although, for a long time, it was believed that hypothyroidism 
secondary to Hashimoto’s thyroiditis was irreversible, some recent studies have proved 
otherwise. This assumption is based on observational studies which revealed a decline in 
titers of thyroid antibodies after the patient was treated with thyroid hormone. Therefore, 
frequent monitoring of thyroid function has been recommended which would help in 
accurately assessing the functional status of the thyroid and enable the physician to make 
necessary changes in the management of the disease (Takasu et al., 1992). Identifying the 
clinical progression of the disease is important in determining the nature of treatment 
provided to each individual. 
The autoimmune nature of Hashimoto’s thyroiditis predisposes patients to concomitant 
development of additional autoimmune diseases. One such autoimmune disorder is 
systemic lupus erythematosus. This particular association was reported as early as 1957 
(Wilkinson & Sacker, 1957) and later studies have confirmed this finding (Weetman & 
Walport 1987; Pyne & Isenberg, 2002). An increased incidence of Hashimoto’s thyroiditis 
has been reported in adults suffering from vitiligo; the risk has been assessed to be 2.5 
times higher when compared to an age-matched population without Hashimoto’s 
thyroiditis (Kakourou et al., 2005). As per Kakourou et al, annual screening for 
Hashimoto’s thyroiditis is recommended in people suffering with vitiligo. Celiac disease, 
an autoimmune disorder of the small intestine, is more common in people with 
autoimmune thyroid disorders when compared to those with other thyroid disorders 
(Cuoco et al., 1999). Chronic idiopathic urticaria, an autoimmune disorder characterized 
by bouts of hives, has also been reported to be associated with Hashimoto’s thyroiditis 
although the pathogenesis of chronic urticaria in Hashimoto’s thyroiditis is not well 
understood. Furthermore, chronic idiopathic urticaria has also been reported in euthyroid 
patients who are seropositive for antithyroid antibodies (Rottem, 2003). In addition, the C-
cells in the thyroid gland, which are responsible for the production of calcitonin, and 
which are involved in the homeostasis of calcium, are damaged by the Hashimoto’s 
thyroiditis disease process. Because of this, patients with Hashimoto’s thyroiditis patients 
have an inherent risk of developing hypocalcemia (Lima et al., 1998). Dyslipedemia has 
also been reported as one of the complications of Hashimoto’s thyroiditis, with thyroid 
stimulating hormone and free T4 hormone levels being inversely correlated with severity 
of lipid abnormality (Tagami et al., 2010).  
Unlike the clear association between Hashimoto’s thyroiditis and other autoimmune 
diseases, the link between Hashimoto’s thyroiditis and cancer is not well delineated. Despite 
the association first being reported in 1951, the link still remains obscure and is a subject of 
debate. In investigating various tumor types, lymphoma and papillary carcinoma of thyroid 
(PTC) are most commonly associated with Hashimoto’s thyroiditis. The incidence of thyroid 
carcinoma in people with Hashimoto’s thyroiditis has been reported to be as high as 36.4% 
(Pino Rivero et al., 2004). Although a chimeric gene rearrangement has been proposed as the 
molecular basis for the development of thyroid carcinoma in the presence of Hashimoto’s 
thyroiditis, recent studies have not supported this supposition. Interestingly, no such 
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rearrangements were detected in patients diagnosed with papillary thyroid cancer in the 
background of Hashimoto’s thyroiditis, while in patients diagnosed first with PTC, the 
prevalence of these rearrangements was found to be 33% (Nikiforova et al., 2002). Unlike 
with production of chimeric gene products, the tumor protein P63  is believed to play a vital 
role in the development of PTC in patients with previously established Hashimoto’s 
thyroiditis. Moreover, supporting evidence can be inferred from the absence of these 
proteins in thyroid tissue devoid of PTC or Hashimoto’s thyroiditis (Unger et al., 2003). 
Similar to PTC, B-cell lymphoma of the thyroid gland has been found to be associated with 
Hashimoto’s thyroiditis. The histological features of this specific lymphoma have been 
found to be similar to those of mucosa associated lymphoid tumors (Hygek & Isaacson, 
1988). 
8. Diagnosis 
Assessing the metabolic status of the patient and identifying the type of lesion present are 
of vital importance in making an accurate diagnosis of Hashimoto’s thyroiditis. The first 
step is to assess the thyroid hormone status, which reflects glandular function. Although 
the presence of goiter alone, without associated hyperthyroid symptoms, is suggestive of 
Hashimoto’s thyroiditis, the presence of a goiter in a hypothyroid patient is considered to 
be strongly indicative of Hashimoto’s thyroiditis. Triiodothyronine (T3), 
tetraiodothyronine (T4) and thyroid stimulating hormone (TSH) levels are the commonly 
employed lab studies used to assess the level of function of the thyroid gland. Among 
these parameters, TSH has been reported to be the most sensitive marker of 
hypothyroidism. Even after the diagnosis is established, frequent monitoring of TSH is 
done to assess the response to treatment and progression of the disease. After the 
assessment of patient’s thyroid function status, the focus shifts to indentifying the 
presence of antithyroid antibodies. It should be noted that while the presence of 
antithyroid peroxidase (ATPO) and antithyroglobulin (TGAB) antibodies are both 
positively correlated with Hashiomoto’s thyroiditis, the correlation is slightly higher for 
TGAB than ATPO. (Kasagi et al., 1996). Even in the absence of hypothyroid symptoms, 
the presence of antithyroid antibodies would indicate underlying lymphocytic infiltration 
of the gland, and be indicative of autoimmune disease (Yoshida et al., 1978). In an attempt 
increase the certainty of the diagnosis, antimicrosomal antibodies have been found to 
afford greater diagnostic accuracy when compared to antithyroglobulin antibodies. 
However, for those cases in which Hashimoto’s thyroiditis is suspected clinically but 
antibody titers are not elevated, fine needle aspiration (FNA) and cytological examination 
continue to play a defining role in establishing the diagnosis (Baker et al., 1982; Kumar et 
al., 2002; Takashi et al., 2008).  
In delineating key cytological findings, extent of lymphocytic infiltration and the presence of 
Hurthle cells has been found to be directly proportional to the severity of the disease. Also, 
as the disease progresses, colloid in the thyroid gland is destroyed and the spaces between 
follicular cells shrink, altering the microscopic appearance of FNA biopsy specimens. In 
further elaboration on how microscopic appearance correlates with disease severity, extent 
of involved tissue has been found to be directly proportional to severity of the disease. 
Despite the diagnostic sensitivity and accuracy of cytological analysis, in some instances, the 
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presence of numerous hyperplastic follicular cells may lead to a false diagnosis of follicular 
carcinoma. Alternatively, the diagnosis of some neoplasms, like Hurthle cell tumor, could be 
misdiagnosed as Hashimoto’s thyroiditis due to the presence of a large number of Hurthle 
cells (MacDonald & Yazdi, 1999). In addition to the above investigations, accurate diagnosis 
must also incorporate clinical correlation. 
Radioactive iodine uptake (RAIU) is another modality which is commonly employed in 
diagnosing thyroid disorders. The role of RAIU in the diagnosis of Hashimoto’s thyroiditis 
has been debated for many years (Cohen et al., 1965). A potentially less obtrusive study 
which may be performed to discern thyroid pathology is an ultrasound. Ultrasonography 
provides information regarding anatomic characteristics of the gland and identifies any 
major changes in the gland. Ultrasonography can be helpful in discerning Hashimoto’s 
thyroiditis in goiters of unknown etiology and can identify the cause of functional 
impairment as well as the necessity for treatment (Sostre & Reyes, 1991).  
The physical characteristics of the thyroid gland, serum TSH levels, serum antithyroid 
antiglobulin titer, radioactive iodine uptake of the gland, and the response to the perchlorate 
discharge test are widely used in making an accurate diagnosis of the disease. Indeed, the 
clinician can feel reasonably confident in their diagnosis of Hashimoto’s thyroiditis if at least 
two of the above mentioned tests support the diagnosis (Fisher et al., 1975). Some recent 
studies have subclassified Hashimoto’s thyroiditis as IgG-4 thyroiditis and nonIgG-4 
thyroiditis. This distinction may be important in that IgG-4 thyroiditis has been associated 
with severe lymphoplasmacytic infiltration, marked fibrosis, and lymphoid follicle 
formation in contrast to nonIgG-4 thyroiditis, which exhibits more mild histopathological 
changes (Li., 2009). Thus, this classification might be helpful in assessing the severity of the 
disease and could be used in determining the most appropriate treatment options for 
patients.  
Furthermore the disease process must be differentiated from some commonly occurring 
thyroid disorders such as nontoxic nodular goiter and Graves’ disease. The presence of a 
multinodular goiter with gross nodularity is usually considered to be evidence against the 
diagnosis of Hashimoto’s thyroiditis but it cannot be ruled out based on this finding 
(Takashi et al., 2008). Unlike Hashimoto’s thyroiditis, multinodular goiter is usually 
characterized by euthyroid status and absence of antithyroid antibodies. Hashimoto’s 
thyroiditis and multinodular goiter commonly coexist in patients thus, FNA is commonly 
employed to differentiate these two entities. Tumor of thyroid gland is another entity which 
has to be differentiated from Hashimotos’ thyroiditis. Rapid growth of the gland and 
persistent pain usually arouses suspicion of tumor. The confirmatory diagnosis of tumor is 
usually performed with the aid of FNA. Thyroid lymphoma may develop in some cases of 
Hashimoto’s thyroiditis. Some studies have indicated that using reverse transcriptase 
polymerase chain reaction might be helpful in differentiating thyroid lymphoma and 
Hashimoto’s thyroiditis (Takano et al., 2000). Furthermore, although Hashimoto’s 
thyroiditis typically presents with hypothyroid symptoms, patients may occasionally 
present with hyperthyroidism and thyrotoxicosis. This necessitates the differentiation of 
Hashimoto’s thyroiditis from Graves’ disease, in cases associated with symptoms of excess 
thyroid hormone. 
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HURTHLE Cells (Metaplastic)               Germinal Center With Plasma Cells and  Lymphocytes 
 
Fig. 3. Histological section thyroid gland affected with Hashimoto’s Disease (Datto & 
Youens, 2007). 
9. Treatment 
Options in the treatment of Hashimoto’s thyroiditis include medical therapy and surgical 
resection of the gland. The appropriate choice depends on disease presentation  and extent 
of gland involvement. In some instances, patients may present without symptoms, and 
may not require immediate intervention. (Vickery & Hamlin, 1961). However, continuing 
debate surrounds whether prophylactic replacement of thyroid hormone has therapeutic 
benefit in euthyroid-appearing patients with Hashimoto’s thyroiditis (Chiovato et al., 
1986).  Recently, studies have shown that prophylactic treatment in euthyroid patients can 
slow the progression of the disease and significantly reduce levels of antithyroid 
antibodies; however, the long-term benefits of this approach have not yet been confirmed 
(Padberg etal 2004). Furthermore, ultrasound studies have shown that thyroid size 
diminishes in response to thyroid hormone replacement, even in euthryoid patients 
(Hegedus et al., 1991). Moreover, reversibility in the progression of the disease appears to 
be quicker and more pronounced in younger patients than in more mature patients. This 
difference may be attributable to the extent of glandular involvement and increased 
degree of fibrosis in older populations, making reversibility of the underlying pathology 
less feasible.  
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Fig. 4. Flow diagram representing the diagnosis of Hashimoto’s thyroiditis 
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After assessment of the functional status of thyroid gland, thyroid hormone replacement 
therapy is instituted in all Hashimoto’s thyroiditis patients with documented 
hypothyroidism. Thyroid hormone replacement is also indicated in the presence of a goiter, 
if the goiter is small in size and is causing minimal pressure symptoms or disfigurement. 
The initial dosage of the thyroid hormone is determined based upon the patient’s body 
mass, cardiovascular condition, concomitant co-morbid conditions and pregnancy status. 
The daily dosing in healthy young individuals is usually calculated as 1.7 
micrograms/Kilogram of body weight per day which typically ranges between 75-125 
micrograms per day. Most hypothyroid patients suffering with Hashimoto’s thyroiditis will 
need lifelong replacement of thyroid hormone. External supplementation of thyroid 
hormone will not only correct the metabolic status of the person but it is also postulated to 
modify the course of the disease. Long term follow up of patients treated with thyroxine has 
shown reduced antithyroid peroxidase antibodies after a mean time of  50 months, with  a 
small number of  patients being reported as seronegative (Schmidt et al., 2008). Moreover, 
about 20% of patients suffering from Hashimoto’s thyroiditis-related hypothyroidism 
recovered normal thyroid function when challenged with thyroid releasing hormone (TRH). 
In addition, a few studies have shown that if patients recover normal thyroid gland 
function, they might remain euthyroid, despite not taking hormone therapy, for a mean 
period of approximately 8 years (Takasu et al., 1990).  
In contrast to hormone replacement therapy, nutritional therapies, which focus on 
modifying the body’s immune response and resultant destruction of thyroid tissue, continue 
to be an area of keen interest. Selenium, a trace element which plays an important role in 
modifying inflammatory and immune responses in the body, has been proposed to have 
disease-modifying properties in Hashimoto’s thyroiditis. The rationale for using this 
nutrient stems from the discovery that the enzymes iodothyronine deiodinase, glutathione 
peroxidase and thioredoxin reductase, which maintain thyroid gland homeostasis, are 
selenium dependant. One study investigating the effect of selenium supplementation on 
Hashimoto’s thyroiditis found significant reduction in the levels of antithyroid peroxidase 
(ATPO) following 6 months of therapy. Further decline in antibody levels was observed 
when the therapy was continued, with antibody levels increasing after therapy was 
terminated. (Mazokapakis et al., 2007).  
In some cases, pharmacotherapy and hormone replacement might not be sufficient to treat 
the symptoms of Hashimoto’s thyroiditis and surgical therapy is required. Surgical therapy 
is indicated in patients suffering from severe, painful goiter or experiencing pressure 
symptoms resulting from tracheal encroachment, which include dysphasia or dyspnea. In 
an attempt to create guidelines for thyroid resection, the following factors have been found 
to play a major role in determining when to pursue surgical resection (Thomas & Rutledge, 
1981): 
1. Dominant mass unresponsive to thyroxine therapy 
2. Increase in the size of the mass despite thyroxine therapy 
3. History or physical examination findings suggestive of malignancy 
4. Indeterminate findings on cutting needle biopsy 
A small group of patients, with Hashimoto’s thyroiditis, present with pain and tenderness 
rather than a goiter or hypothyroidism. Thyroidectomy has been proven to be effective in 
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these patients as treatment with thyroid hormone replacement or corticosteroids will not 
alleviate their symptoms (Kon & Degroot, 2003). Painful Hashimoto’s thyroiditis is an 
atypical variant characterized by recurrent attacks of fever and thyroid pain in the 
presence of antithyroid antibodies. These cases do not respond to the regular anti-
inflammatory agents, which have been found to be effective in controlling pain associated 
with other forms of thyroiditis. In assessing the risk/benefit trade-off of thyroid resection, 
the complication risk involved in performing thyroidectomy in patients with Hashimoto’s 
thyroiditis is reported to be very low, but the presence of unsuspected coexisting 
malignancies is common (Shih et al., 2008). Moreover, prophylactic removal of a nodular 
thyroid gland is done in selected cases to prevent the development of thyroid cancer, 
which would be typically diagnosed at a later stage. It should be noted that the 
effectiveness of this approach has been widely debated and remains a point of research 
interest. In cases with documented thyroid cancer, removal of the gland followed by 
radiotherapy or chemotherapy, depending on the type of tumor, is the definitive therapy. 
The presence of tumors coexistent with Hashimoto’s thyroiditis does not alter surgical 
management when compared to cases of Hashimoto’s thyroiditis uncomplicated by 
neoplasm (Singh et al., 1999). Surgical removal of the thyroid gland has been tried with 
variable success in cases of Hashimoto’s thyroiditis associated with chronic urticaria, 
when anti-allergic and corticosteroid therapies have proven ineffective. Briefly 
summarized; thyroid hormone status, pressure symptoms associated with an enlarged 
gland, and presence of associated symptoms or other autoimmune disorders should be 
considered in making an accurate treatment choice. 
10. Hashimoto’s encephalopathy 
Hashimoto’s encephalopathy or encephalitis is a rare neuroendocrine entity and is 
described as an autoimmune encephalopathy, which occurs in patients diagnosed with 
Hashimoto’s thyroiditis. Similar to Hashimoto’s thyroiditis, it can affect individuals of all 
age groups, and is more common in women than in men. Hashimoto’s encephalopathy is 
frequently misdiagnosed since symptoms at presentation are predominantly neurological. 
Some cases have been reported where patients presented with Hashimoto’s 
encephalopathy long before there was any clinical suspicion for Hashimoto’s thyroiditis 
(Peschen-Rosin et al., 1999). Hashimoto’s encephalopathy was first described in 1961, in a 
48 year-old man who was hypothyroid and who experienced recurring episodes of 
encephalopathy and stroke-like symptoms (Brain et al., 1966). Some authors prefer using 
the term corticosteroid-responsive encephalopathy rather than Hashimoto’s 
encephalopathy as the pathogenesis of this condition is still a topic of widespread 
conjecture (Fatourechi, 2005). The estimated prevalence of this condition is 2.1/100,000 
(Ferracci & Giani, 2003). The actual prevalence of the disease could be much higher since 
many cases of Hashimoto’s encephalopathy are presumed to remain undiagnosed. Studies 
attempting to describe the pathophysiological mechanisms behind this condition have 
suggested the possible role of autoimmune processes. Similar to Hashimoto’s thyroiditis, 
patients with Hashimoto’s encephalopathy have high levels of antithyroid antibodies and 
respond to immunosuppressive therapy, supporting the involvement of an autoimmune 
mechanism in its pathogenesis (Schiess & Pardo, 2008). An underlying immune 
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mechanism is further supported by autopsy studies which revealed histopathological 
changes such as lymphocyte infiltration of the leptomeninges, and gliosis of cortical gray 
matter, basal ganglia, thalamus and hippocampus, which are reminiscent of autoimmune 
injury to other organs of the body (Duffey & Yee, 2003). The presentation of Hashimoto’s 
encephalopathy can be either acute or subacute, and is characterized by a relapsing-
remitting or progressive course of seizures, tremors, ataxia, myoclonus, psychosis, and 
stroke-like neurological findings. The literature indicates that the initial clinical 
presentation can be classified either as a vasculitic type, with predominantly stroke-like 
symptoms and mild cognitive impairment, or a diffuse progressive type with 
predominant cognitive impairment (Kothbauer-Marggreiter et al., 1996). In contrast to 
disease prevalence findings in adults, very few instances of Hashimoto’s encephalopathy 
have been reported in the pediatric age group. Pediatric Hashimoto’s encephalopathy is 
characterized by seizures, hallucinations, and confusion, and suspicion should arise when 
a progressive decline in school performance is observed (Vasconcellos et al., 1998).  
The diagnosis of Hashimoto’s encephalopathy continues to be a diagnosis of exclusion. 
Serum titers of antithyroid antibodies will be elevated and cerebrospinal fluid analysis 
will show increased protein levels. Other possible causes of encephalopathy including 
infections, metabolic and electrolyte derangements, toxic ingestions, vascular 
abnormalities, and neoplastic or paraneoplastic syndromes must be ruled out before a 
Hashimoto’s encephalopathy diagnosis is made. Electroencephalogram and imaging 
studies in patients with suspected Hashimoto’s encephalopathy typically exhibit 
nonspecific changes, in the absence of infection, tumor, or stroke (Marshall & Doyle, 
2006). The antibody titers in Hashimoto’s encephalopathy are not suggestive of the 
severity or the type of clinical presentation. Early diagnosis and prompt intervention are 
of critical importance in effectively treating this condition, and significantly reducing its 
morbidity and mortality. The first line of treatment is usually corticosteroids, and in cases 
where steroids are contraindicated, other immunosuppressive agents have been employed 
with good efficacy. In steroid unresponsive cases, administration of plasmapheresis has 
been shown effective in controlling symptoms (Nagpal & Pande, 2004). Periodic 
intravenous exchange may also be used for steroid non-responders, but no superiority has 
been established when compared to plasmapheresis. The duration of the treatment is 
highly variable, however approximately 90% of the cases will remain in remission after 
treatment. 
11. Conclusion 
In this chapter, we have discussed the epidemiology, presumed pathogenesis, diagnosis and 
treatment of Hashimoto’s thyroiditis. We have also discussed potential complications 
including other autoimmune diseases and neoplasms. In many ways, Hashimoto’s 
thyroiditis serves as a paradigm for autoimmune disease throughout the body. Our 
understanding of how a genetic predisposition can be modified by environmental exposure 
is expanding. Our grasp of how aggressive immune suppression can alter disease course is 
growing. As with many subjects in medicine, with knowledge comes more questioning of 
what we know. Just as in other disease states, we must eagerly seek out both the questions 
and the answers. 
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